The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience

Basit Öğe Kaydı
dc.contributor.authorÖneç, Birgul
dc.contributor.authorOkutan, Harika
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorCan, Esra Sarıbacak
dc.contributor.authorAslan, Vedat
dc.contributor.authorKoluman, Başak Ünver
dc.contributor.authorKöş, Durdu Mehmet
dc.date.accessioned2020-04-30T23:34:03Z
dc.date.available2020-04-30T23:34:03Z
dc.date.issued2017
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionalbayrak, murat/0000-0003-4025-741X; Onec, Birgul/0000-0003-2824-1044en_US
dc.descriptionWOS: 000397489300008en_US
dc.descriptionPubMed: 27500465en_US
dc.description.abstractBackgroundRecent studies have shown a positive correlation between tumor-related immune response markers and the poor outcome in solid tumors. In this study, we aimed to investigate the neutrophil/lymphocyte ratio (NLR) in multiple myeloma. To the best of our knowledge, this would be the second report concerning this topic. MethodsWe retrospectively reviewed the data for 52 multiple myeloma patients. The patients were grouped using the baseline NLR as NLR 1.72 and NLR > 1.72 using receiver operating characteristic analysis to determine a cut off. We compared the two groups in terms of both the known prognostic factors of the myeloma and the overall survival (OS). ResultsOur study showed that NLR is associated with C-reactive protein and 2 microglobulin (P = 0.02 and P = 0.001, respectively). The patients with NLR > 1.72 had significantly worse stages, performance status, and kidney functions. The whole group's OS was estimated as 35.1 months while the patients with lower NLR had better OS when compared with those with NLR > 1.72 (42.75 and 26.14 months, respectively, P: 0.04). ConclusionNeutrophil/lymphocyte ratio, which is associated with stage, performance status, and kidney functions, can be used in daily practice as a predictor for survival in multiple myeloma. Simply adding NLR to the routine charts may enrich our data for larger studies.en_US
dc.identifier.doi10.1002/jcla.22032en_US
dc.identifier.issn0887-8013
dc.identifier.issn1098-2825
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1002/jcla.22032
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5093
dc.identifier.volume31en_US
dc.identifier.wosWOS:000397489300008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Clinical Laboratory Analysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectmultiple myelomaen_US
dc.subjectneutrophilen_US
dc.subjectlymphocyte ratioen_US
dc.subjectprognosisen_US
dc.subjecttreatment outcomeen_US
dc.titleThe Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5093.pdf
Boyut:
138.46 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu